News

According to a study published on September 22nd by U.S. researchers, those who had COVID-19 were more likely to experience a variety of brain damage a year later than those who had never had the coronavirus. This result may have...

Greenphire, the global leader in financial lifecycle management for clinical trials, announced results from its 2022 annual market trends survey which examined top challenges and opportunities for sponsors, CROs, and sites across the globe. While survey respondents represented a...

A quarter of patients with a variety of advanced tumours have shown signals of benefit from RP2, a modified form of the herpes simplex virus, according to research. The trial's participants had malignancies of the head and neck, oesophagus,...

The fixed-dose combination Opdualag (nivolumab and relatlimab) from Bristol Myers Squibb (BMS) has received clearance from the European Commission for use as the first-line therapy for advanced unresectable or metastatic melanoma. Patients aged 12 years and older who have cancer...

According to Chief Executive Seth Berkley of the global vaccination alliance GAVI, the organisation has set up financial structures that would enable it to quickly access pledged donor cash in the event that it needs to purchase vaccines for...

Within one firm, the title of most costly treatment in the world has changed hands within a month. Bluebird Bio has received an FDA fast clearance for Skysona, also known as eli-cel, for the uncommon neurological condition cerebral adrenoleukodystrophy (CALD),...

QIAGEN and Neuron23TM Inc., an early-stage biotechnology company focused on creating precision medications for genetically defined neurological and immunological illnesses, have announced a partnership to create a companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease. According to the terms...